Successful Treatment of Antimony-Resistant Cutaneous Leishmaniasis with Liposomal Amphotericin B

Cutaneous leishmaniasis is endemic in the Mediterranean area. Increases in the numbers of international travelers and immigrants have resulted in more cases in countries where the disease is not endemic. The pentavalent antimonial compounds are the principal therapeutic agents used for cutaneous lei...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1994-06, Vol.18 (6), p.1024-1025
Main Authors: Torre-Cisneros, Julían, Prada, José Luís, Villanueva, José Luís, Valverde, Francisco, Sánchez-Guijó, Pedro
Format: Article
Language:English
Subjects:
Adult
Amphotericin B - analogs & derivatives
Amphotericin B - therapeutic use
Antimony - therapeutic use
Correspondence
Cutaneous leishmaniasis
Dosage
Drug Resistance
Female
Humans
Leishmania
Leishmaniasis
Leishmaniasis, Cutaneous - drug therapy
Liposomes
Visceral leishmaniasis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cutaneous leishmaniasis is endemic in the Mediterranean area. Increases in the numbers of international travelers and immigrants have resulted in more cases in countries where the disease is not endemic. The pentavalent antimonial compounds are the principal therapeutic agents used for cutaneous leishmaniasis. Use of second-line treatments for resistant cases is complicated by toxicity. We report the successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B.
ISSN:1058-4838
1537-6591
DOI:10.1093/clinids/18.6.1024